Stem cell therapy for COVID‐19, ARDS and pulmonary fibrosis
Review
[키워드] acute respiratory distress
acute respiratory syndrome
alveolar epithelial cell
ARDS
cause
caused
Cell
clinical trial
clinical trials
coronavirus
Coronavirus disease 2019
COVID‐19
COVID‐19 patient
COVID‐19
CRS
Cytokine release syndrome
Cytokines
derivative
Efficacy
endothelial
Exosomes
Factor
Factors
FGF
fibroblast
function
growth
hearts
HGF
illnesses
immune cells
immune system
KGF
lung
Mesenchymal stem cells
MSC
MSCs
MSCs therapy
Necrosis
other organ
paracrine
Pathogenesis
pathogenic
Patient
potential mechanism
Potential treatment
preclinical studies
preclinical study
progression
promote
PROTECT
Protein
pulmonary fibrosis
quantified
Registered
regulate
respiratory infectious disease
SARS‐CoV‐2
secrete
secreting
secretion
shown
stem cell
Stem cell therapy
suggested
supportive care
syndrome
the disease
therapeutic
therapeutic potential
therapy
tissue repair
TNF‐α
Treatment
variety
Vascular
VEGF
[DOI] 10.1111/cpr.12939 PMC 바로가기 [Article Type] Review
[DOI] 10.1111/cpr.12939 PMC 바로가기 [Article Type] Review